Blood cancers

MRD is ‘measurable’ not ‘minimal’ residual disease: new consensus recommendations

A panel of international experts has proposed dropping the term ‘minimal’ residual disease alongside other recommendations to standardise nomenclature and assessment of measurable residual disease (MRD) as an indicator of disease burden in chronic lymphocytic leukaemia (CLL), in light of emerging treatments able to achieve deep remission. In an article published in Leukaemia, a research ...

Already a member?

Login to keep reading.

© 2022 the limbic